Cargando…

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia

Objectives: To perform a pharmacokinetic/pharmacodynamic (PK/PD) analysis of continuous-infusion (CI) fosfomycin combined with extended-infusion (EI) cefiderocol or CI ceftazidime-avibactam in a case series of severe difficult-to-treat Pseudomonas aeruginosa (DTR-PA) infections. Methods: A single-ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatti, Milo, Giannella, Maddalena, Rinaldi, Matteo, Gaibani, Paolo, Viale, Pierluigi, Pea, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774893/ https://www.ncbi.nlm.nih.gov/pubmed/36551398 http://dx.doi.org/10.3390/antibiotics11121739

Ejemplares similares

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis
por: Gatti, Milo, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
por: Lorente, L, et al.
Publicado: (2005)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
por: Gatti, Milo, et al.
Publicado: (2023)

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases
por: Gatti, Milo, et al.
Publicado: (2022)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2021)

Continuous infusion versus intermittent bolus of ceftazidime for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2003)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Continuous Intravenous Infusion
por: Farquharson, Eric L.
Publicado: (1934)

Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation
por: Mariat, Christophe, et al.
Publicado: (2006)

Meropenem: continuous or extended infusion?
por: Frippiat, Frédéric, et al.
Publicado: (2020)

Continuous IV infusion of anakinra
por: Saunders, Brittney N., et al.
Publicado: (2023)

Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients
por: Maluangnon, Chailat, et al.
Publicado: (2022)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Continuous fluid infusion per rectum compared with intravenous fluid infusion in pigs
por: Chigerwe, Munashe, et al.
Publicado: (2023)

Concomitant continuous infusion chemotherapy and radiation /
Publicado: (1991)

Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the race
por: Lin, Hsin, et al.
Publicado: (2015)

Comparison of Continuous Wound Infusion versus Continuous Epidural Infusion in Upper Abdominal Surgery: Noninferiority Randomized Controlled Trial
por: Thangavel, Arun Raja, et al.
Publicado: (2019)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales
por: Merad, Yanis, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Continuous Insulin Infusion: When, Where, and How?
por: Kelly, Janet L.
Publicado: (2014)

Treatment of Severe Hypertriglyceridemia with Continuous Insulin Infusion
por: Rodríguez Santana, Yesica, et al.
Publicado: (2011)

Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification
por: Benini, Anna, et al.
Publicado: (2021)

Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis
por: Yu, Zhenwei, et al.
Publicado: (2018)

Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria
por: Prinz, Carolin, et al.
Publicado: (2023)

P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
por: Kmentt, Laura, et al.
Publicado: (2023)

In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India
por: Jena, Jayanti, et al.
Publicado: (2023)

Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study
por: Xu, Jinhui, et al.
Publicado: (2022)

Rebound hypotension following terlipressin bolus infusion can be prevented by continuous low-dose infusion of terlipressin
por: Lange, M, et al.
Publicado: (2007)

An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?
por: Baker, J., et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam
por: Koumaki, Vasiliki, et al.
Publicado: (2023)

Amphotericin B used as a continuous infusion is safer
por: Streefkerk, J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eepu69mevu8tg1q175lhluhah0